Our Insights
Insights
Discover the latest insights from Capstone analysts offering perspectives on policy and regulatory issues that we believe investors and businesses underappreciate. Our thought-provoking analyses are designed to empower leaders to navigate complex challenges and drive successful outcomes.
European Biomethane Tracker
Capstone believes European countries will continue to support biomethane (renewable natural gas, or RNG) production, driving further growth in...
The Midterms Debate on Healthcare
On October 20th, Capstone moderated a debate between two former members of Congress, one Republican and one Democrat, on the healthcare outlook...
How SpaceX is Adding Drama to FCC Spectrum Policy
The three biggest US mobile carriers, AT&T Inc. (T), Verizon Communications Inc. (VZ), and T-Mobile US Inc. (TMUS), have spent more than $200...
Youth Sports, Private Equity, State Scrutiny, and the Shifting Policy Backdrop at Play
Few issues garner genuine bipartisan agreement amid widening political divisions in Washington, but access to youth sports transcends the divide....
Untangling the Outlook for NIH Funding and Its Impact on Pharma
Capstone believes funding for the National Institutes of Health (NIH) will remain stable for the next 3-5 years, and investors should look past...
The IRS Ruling Targeting Tax-Aware ETF Strategies
We believe the Internal Revenue Service’s (IRS) September 28th ruling taxing certain Section 351 transactions signals further restrictions on other...
What Regulators Are Doing About Insurer Investment in Private Assets
Capstone believes the National Association of Insurance Commissioners (NAIC) is approaching life insurer investment in complex assets through...
The Emerging Packaging Laws Boxing in Producers on Costs
Momentum for legislation governing extended producer responsibility (EPR) for plastics and packaging has been gathering steam in states with solid...
FDA Cracks Down on GLP-1 Compounding While Bolstering Peptides and Hormone Therapies
Capstone believes that while continued scrutiny by the Food and Drug Administration (FDA) has ended large-scale GLP-1 compounding, non-GLP-1 product...
EXPLORE
Capstone Visuals
The essence of Capstone research, distilled into a quickly digestible graphic. The bottom line—in full color.
Contact Us
































